Metabolic syndrome
Conditions
Interventions
Curcuminoids (1000 mg/day)
Placebo
Sponsors
Clinical Trial Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
Mashhad University of Medical Sciences, Mashhad, Iran
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Diagnosis of metabolic syndrome based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) guidelines a follows: >= 3 of the following conditions: waist circumference >= 102 cm (male) or >= 88 cm (female), blood pressure >= 130/85 mmHg, triglycerides >= 1.7 mmol/L, HDL-C < 1.03 mmol/L (males) or < 1.29 mmol/L (females), fasting plasma glucose (FPG) >= 6.1 mmol/L.
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding, non-compliance with the study medication (defined as not using the medication for > 1 week), participation in a concomitant trial, hypersensitivity to the study medication, presence of malignancies and Impossibility to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum levels of total cholesterol, LDL- cholesterol, HDL-cholesterol, triglycerides, lipoprotein(a), small-dense LDL and non-HDL-cholesterol | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in serum levels of adiponectin, leptin, C-reactive protein, malondialdehyde, superoxide dismutase, tumor necrosis factor-alpha, transforming growth factor-beta, interleukin-6 and monocyte chemoattractant protein-1 | — |
Countries
Asia(except Japan)
Contacts
Public ContactAmirhossein Sahebkar
Mashhad University of Medical Sciences, Mashhad, Iran Biotechnology Research Center
Outcome results
None listed